Saltar al contenido
Merck

PZ0387

PF-562,271

≥98% (HPLC)

Sinónimos:

N-(3-(((2-((2,3-Dihydro-2-oxo-1H-indol-5-yl)amino)-5- (trifluoromethyl)-4-pyrimidinyl)amino)methyl)-2-pyridinyl)-N-methyl-methanesulfonamide benzenesulfonate, PF 562271, PF-00562271, PF-562271

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C21H20F3N7O3S · C6H6O3S
Número CAS:
939791-38-5
Peso molecular:
665.66
UNSPSC Code:
41121800
NACRES:
NA.77
MDL number:
MFCD14105612
Assay:
≥98% (HPLC)
Form:
powder

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

PF-562,271, ≥98% (HPLC)

InChI

1S/C21H20F3N7O3S.C6H6O3S/c1-31(35(2,33)34)19-12(4-3-7-25-19)10-26-18-15(21(22,23)24)11-27-20(30-18)28-14-5-6-16-13(8-14)9-17(32)29-16;7-10(8,9)6-4-2-1-3-5-6/h3-8,11H,9-10H2,1-2H3,(H,29,32)(H2,26,27,28,30);1-5H,(H,7,8,9)

SMILES string

CN(S(=O)(C)=O)C1=NC=CC=C1CNC2=C(C(F)(F)F)C=NC(NC3=CC4=C(C=C3)NC(C4)=O)=N2.O=S(C5=CC=CC=C5)(O)=O

InChI key

LKLWTLXTOVZFAE-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to brown

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Application

PF-562,271 has been used as a focal adhesion kinase (FAK) inhibitor to study its effects on the S100A9-induced tumor cell invasion in prostate cancer cell lines. It has also been used to study its effects on syndecan-1 (SDC-1) knockdown-induced upregulation of early growth regulator 1 (EGR1) in colon cancer cells.

Biochem/physiol Actions

PF-562,271 is a potent, ATP-competitive, reversible and selective inhibitor of FAK and Pyk2. PF-562,271 inhibits FAK phosphorylation in vivo.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000187467
0000187467
0000120492
0000089342
0000073076

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Brittelle E Kessler et al.
Molecular cancer research : MCR, 14(9), 869-882 (2016-06-05)
There are limited therapy options for advanced thyroid cancer, including papillary and anaplastic thyroid cancer (PTC and ATC). Focal adhesion kinase (FAK) regulates cell signaling by functioning as a scaffold and kinase. Previously, we demonstrated that FAK is overexpressed and
Sampath Kumar Katakam et al.
Frontiers in oncology, 10, 774-774 (2020-06-02)
The heparan sulfate proteoglycan Syndecan-1 binds cytokines, morphogens and extracellular matrix components, regulating cancer stem cell properties and invasiveness. Syndecan-1 is modulated by the heparan sulfate-degrading enzyme heparanase, but the underlying regulatory mechanisms are only poorly understood. In colon cancer
Kimberleve Rolón-Reyes et al.
PloS one, 10(6), e0131059-e0131059 (2015-06-23)
Glioblastoma is one of the most aggressive and fatal brain cancers due to the highly invasive nature of glioma cells. Microglia infiltrate most glioma tumors and, therefore, make up an important component of the glioma microenvironment. In the tumor environment
Jayme B Stokes et al.
Molecular cancer therapeutics, 10(11), 2135-2145 (2011-09-10)
Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells. Focal adhesion kinase (FAK) is activated in PDA, and levels are inversely associated with survival. We investigated the effects of PF-562,271 (a small-molecule inhibitor of FAK/PYK2) on (i) in
Zhonghua Lv et al.
OncoTargets and therapy, 13, 6443-6452 (2020-09-05)
S100A9, which is expressed in prostate cancer, has been reported in association with prostate cancer progression. However, the role of S100A9 in prostate cancer metastasis is largely unknown. The aim of this study was to investigate the effect of S100A9

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico